



国内版

国际版

Novel Pharmacological Therapy in Type 2 Diabetes Mellitus with Established Card



All

Images

Videos

翻译成中文

关闭取词

145,000 Results

Any time ▾

## Type 2 diabetes and cardiovascular disease: Have all risk ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127581>

Aug 15, 2014 · **Diabetes mellitus** is a chronic condition that occurs when the body cannot produce enough or effectively use of insulin. Compared with individuals without **diabetes**, patients with **type 2 diabetes mellitus** have a considerably higher risk of **cardiovascular** morbidity and mortality, and are disproportionately affected by **cardiovascular disease**.

Cited by: 260

Author: Iciar Martín-Timón, Cristina Sevillano-Coll...

Publish Year: 2014

## New pharmacological strategies for protecting kidney ...

[https://www.thelancet.com/journals/landia/article/PIIS2213-8587\(18...](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(18...)

Effects of empagliflozin on the **urinary albumin-to-creatinine** ratio in patients with **type 2 diabetes** and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.

Cited by: 2

Author: Marcel H A Muskiet, David C Wheeler, Hi...

Publish Year: 2018

## Novel Pharmacologic Treatments for Cardiovascular Disease ...

<https://www.uscjournal.com/articles/novel-pharmacologic-treatments> ▾

As **evidence** accumulates, SGLT-2 inhibitors may become first-line or co-first-line with metformin in patients with both **established cardiovascular disease** and **type 2 diabetes mellitus**.

## Reducing cardiovascular risk in patients with type 2 ...

<https://www.sciencedirect.com/science/article/pii/S1357303918302834>

**Epidemiology** of **diabetes mellitus** and **cardiovascular disease**. A total of 387 million people, 8.3% of adults worldwide, have T2DM. In 2014, 4.9 million people died from **complications** of **diabetes**, and it is

**Name of Journal:** *World Journal of Diabetes*

**Manuscript NO:** 47997

**Manuscript Type:** MINIREVIEWS

**Novel pharmacological therapy in type 2 diabetes mellitus with established cardiovascular disease: Current evidence**

Leonardo Pozo, Fatimah Bello, Andres Suarez, Francisco E Ochoa-Martinez, Yamely Mendez, Chelsea H Chang, Salim Surani

### Abstract

Cardiovascular diseases remain the leading cause of death in the world and in most developed countries. Patients with Type 2 Diabetes Mellitus (T2DM) suffer from both microvascular and macrovascular diseases and therefore have higher rates of morbidity

### Match Overview

1	Internet 26 words crawled on 22-Feb-2019 <a href="http://www.powerpak.com">www.powerpak.com</a>	1%
2	Internet 22 words crawled on 26-Mar-2019 <a href="http://renal.org">renal.org</a>	<1%
3	Crossref 20 words Daniel A. Hussar, Dean R. Wetty, "New Drugs: Dulaglutide, olodaterol hydrochloride, and vorapaxar sulfate", Jour	<1%
4	Internet 19 words crawled on 26-Mar-2019 <a href="http://orbi.uliege.be">orbi.uliege.be</a>	<1%
5	Internet 18 words crawled on 11-Dec-2018 <a href="http://wikijournalclub.org">wikijournalclub.org</a>	<1%
6	Internet 18 words crawled on 16-Aug-2018 <a href="http://www.lapislight.com">www.lapislight.com</a>	<1%
7	Crossref 17 words Jagriti Upadhyay, Stergios A. Polyzos, Nikolaos Perakakis, Bindiya Thakkar et al. "Pharmacotherapy of Type 2 Dia	<1%
8	Crossref 17 words Hong Ding, Chris R. "Chapter 6 Glycaemic Control and Protection of the Vasculature from Glucose Toxicity", InTe	<1%
9	Internet 17 words crawled on 24-Feb-2019 <a href="http://www.nejm.org">www.nejm.org</a>	<1%
10	Internet 15 words crawled on 27-Nov-2017 <a href="http://link.springer.com">link.springer.com</a>	<1%
11	Internet 15 words crawled on 30-Jun-2017 <a href="http://clinicaltrials.gov">clinicaltrials.gov</a>	<1%



国内版

国际版

Novel pharmacological therapy in type 2 diabetes mellitus with established cardiac



All

Images

Videos

翻译成中文

关闭取词

280,000 Results

Any time ▾

## Type 2 diabetes and cardiovascular disease: Have all risk ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4127581>

Aug 15, 2014 · DM is a **well-established risk factor** for cardiovascular disease (CVD). People with **type 2 diabetes mellitus** (T2DM) have a higher **cardiovascular morbidity and mortality**, and are disproportionately affected by CVD compared with **non-diabetic** subjects[3].

Cited by: 267

Author: Iciar Martín-Timón, Cristina Sevillano-Coll...

Publish Year: 2014

## Novel Pharmacologic Treatments for Cardiovascular Disease ...

<https://www.uscjournal.com/articles/pharmacologic-treatment-cardiovascular> ▾

Aug 30, 2017 · SGLT-2 inhibitors should be considered second-line therapies to metformin for patients **with established** or elevated risk for **cardiovascular disease** and **type 2 diabetes mellitus**. 26 Patients with low blood pressure or orthostatic hypotension, severe renal impairment (estimated glomerular filtration rate <30 mL/min per 1.73 m<sup>2</sup>) or a history of ...

Author: Leo Buckley, Ahmed Aldemerdash

## New pharmacological strategies for protecting kidney ...

[https://www.thelancet.com/journals/landia/article/PIIS2213-8587\(18\)30263-8/fulltext](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(18)30263-8/fulltext)

Dec 19, 2018 · **Type 2 diabetes** is the leading cause of impaired kidney function, albuminuria, and renal replacement **therapy** globally, thus placing a large burden on health-care systems. **Current treatment strategies** rely on intensive glucose lowering as well as strict blood pressure control through blockade of the renin–angiotensin–aldosterone system. Such approaches might slow decline in kidney function ...

Cited by: 2

Author: Marcel H A Muskiet, David C Wheeler, Hi...

Publish Year: 2019

## Pharmacologic Therapy for Type 2 Diabetes | Annals of ...

<https://annals.org/aim/fullarticle/2609290/pharmacologic-therapy-type-2-diabetes> ▾

Apr 18, 2017 · Major **cardiovascular** outcomes trials have studied patients with **type 2 diabetes** and **established cardiovascular disease**, including EMPA-REG (Empagliflozin Cardiovascular Outcome Event Trial in **Type 2 Diabetes Mellitus** Patients) and the LEADER (Liraglutide Effect and Action in **Diabetes**: Evaluation of Cardiovascular Outcome Results) trial . These ...

Cited by: 33

Author: James J. Chamberlain, William H. Herra...

Publish Year: 2017

## Pharmacologic Management of Type 2 Diabetes Mellitus ...

<https://www.sciencedirect.com/science/article/pii/S0002914917307993>